Thyroid-stimulating hormone-receptor antibody and thyroid hormone concentrations in smokers vs nonsmokers with Graves disease treated with carbimazole.
暂无分享，去创建一个
M. Nyirenda | G. Beckett | A. Toft | P. Taylor | M. Stoddart
[1] N. Benowitz,et al. Effect of pregnancy on a measure of FMO3 activity. , 2005, British journal of clinical pharmacology.
[2] N. Takasu,et al. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. , 2000, Thyroid : official journal of the American Thyroid Association.
[3] M. Prummel,et al. Smoking and Risk of Gravesʼ Disease , 1993 .
[4] S Senn,et al. Analysis of serial measurements in medical research. , 1990, BMJ.
[5] A. McGregor,et al. Carbimazole and the autoimmune response in Graves' disease. , 1980, The New England journal of medicine.
[6] D. Mclarty,et al. The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients. , 1980, British journal of clinical pharmacology.